New report on Nickel allergy

Nickel allergy and EU nickel restriction workshop report from the Nickel Institute

NACD WS Report Brussels June 2017

See Report

THIS SKIN RASH IS SERIOUS!

SKINSERIOUS – report your experience with Dermatitis, Evaluation, Impact of Patch Testing on your Diagnosis and Care.

This weekend marked a magnificent occasion… The revival of the American Contact Dermatitis Society Mid-Year meeting — more than a decade after the last such meeting. This meeting FRONTIERS in DERMATITIS was attended by dermatologists, allergists, scientists from all over the country. We heard from Past-Surgeon General and Dermatologist Boris Lushniak MD “Reflections from my time as Surgeon General” and interfaced with Linda Katz, MD/MPH from the FDA “FDA Update on Cosmetics”, and Past-president of the ACDS, Bruce Brod MD on the importance of representing Contact Dermatitis in the House of Medicine at the AMA.

We are supporting the American Academy of Dermatology’s campaign to share stories about skin conditions — PLEASE report your experience with Dermatitis, Evaluation, Impact of Patch Testing on your Diagnosis and Care:

SKINSERIOUS Link

or for ease – we placed it on the Dermatitis Academy patient resource page.

 

New article Free – limited time: Staph infections in AD and Nickel allergy

Staphylococcal infections in atopic dermatitis and nickel allergy: Immunologic implications and elemental opportunities

PLEASE NOTE THE ARTICLE SHOULD READ:
NON-Alkaline soaps, diluted vinegar soaks, and colloidal oatmeal emollients have been shown to decrease the pH of the skin.

Free access from Elsevier

FREE- New Article on TSW!

Systematic Review of the Topical Steroid Addiction and Topical Steroid Withdrawal Phenomenon in Children Diagnosed With Atopic Dermatitis and Treated With Topical Corticosteroids

Juhász, Margit L. W.; Curley, Rosemarie A.; Rasmussen, Annelise; Malakouti, Mona; Silverberg, Nanette; Jacob, Sharon E.

Background: A 2015 National Eczema Association study concluded that topical steroid withdrawal is an effect of prolonged, frequent use of topical steroids occurring mostly in adult women. It is unclear whether children develop topical steroid withdrawal.

Objective: The aim of this study was to assess current evidence regarding topical steroid withdrawal in children.

Methods: This study is a systematic review of medical literature as well as online social media sites and blogs regarding topical steroid withdrawal in children.

Results: Literature search yielded zero studies on/or reporting classic topical steroid withdrawal in children; however, periorificial dermatitis, which is generally a steroid-induced disorder in children, was reported in >320 cases. Of 142 social media blogs on topical steroid withdrawal, 26 were blogs discussing children. Twenty-seven cases were included in this review. Length of topical steroid use ranged from 2 months to 12 years.

Conclusions: Topical steroid withdrawal occurs in children and can result from discontinuing topical steroids used for as little as 2 months. Resultant signs/symptoms can last >12 months, even with short duration of use. Clinicians and caregivers should be aware of this possible adverse effect of topical steroids and monitor the effects of topical steroids on infants/children, but more data are needed on this condition.

 

Read it here – FREE for 30days – please share

The Dermatologist – Features Regional Atlas on Contact Dermatitis

The Dermatologist is a print and digital brand that circulates to more than 14,798 dermatologists, dermatology residents, dermatology nurse practitioners, physician assistants and nurses, as well as other healthcare professionals. The Dermatologist is collaborating with numerous associations, including the National Psoriasis Foundation, the world’s leading patient advocacy organization dedicated to the 7.5 million Americans with psoriasis and psoriatic arthritis, to educate dermatologists on the latest research related to psoriasis through The Dermatologist print and digital brand. Others include The National Eczema Association, The National Rosacea Society, and The Skin Cancer Foundation.

The editorial mission of The Dermatologist  focuses on providing practical and clinical insight, industry news and peer perspectives into today’s general dermatology issues. This award-winning publication offers dermatologists reader-friendly, timely and informative articles that highlight clinical advances for treatment of cutaneous pathologies such as skin cancer, acne and psoriasis, as well as information on how to incorporate cosmetic procedures, such as Botox and laser skin resurfacing, into a dermatology practice. Practice management topics, such as managed care, Medicare regulations and marketing techniques that can easily be translated into current practice settings, are also featured.”

Check out the Regional Atlas of Contact Dermatitis!

The Dermatologist (formerly Skin and Aging) has had a column dedicated to allergic contact dermatitis (allergen focus) since January 2005!

Experimental T cell regulation in ACD – novel potential interventions

Original Article: Balmert SC, Donahue C, Vu JR, Erdos G, Falo LD Jr, Little SR. In vivo induction of regulatory T cells promotes allergen tolerance and suppresses allergic contact dermatitis. J Control Release. 2017 Sep 10; 261:223-233.

Reviewer: Calvin T Sung, BS. MSIII, University of California Riverside School of Medicine

  • Allergic contact dermatitis (ACD) is a T-cell mediated inflammatory skin condition commonly treated with topical corticosteroids through nonspecific immunosuppression.
  • The underlying immune hypersensitivity dysfunction can be addressed through identification and avoidance of the causative agent.
  • Essentially, ACD results from an inbalance between immune suppressing T regulatory cells (Tregs) and the pro-inflammatory cells that are inappropriately responding to specific allergens.
  • Immunologial chemical messengers, aka cytokines, (IL-2 and TGF-b1) and the antibiotic rapamycin can promote the expansion of Tregs to suppress the over active immune function underlying ACD.
  • Microparticle polymers are notable large molecules that can carry and release IL-2, TGF-b1, and rapamycin.
    • Balmert et al demonstarted that a Poly(ethylene glycol)-poly(lactic-co-glycolic acid) microparticle (PEG-PLGA) had a faster release rate of IL-2, TGF-b1, and rapamycin compared to the original PLGA microparticle formulation previously described by Jhunjhunwala et al.1
    • The cytokine and antibiotic releasing microparticle treatment was formulated as a subcutaneous injection and delivered experimentally to mice two days prior to topical and microneedle delivered allergen exposure (to induce sensitization).
    • Microparticle treatment injections at the ear (where allergens were introduced) revealed the potential for increasing the number of local Tregs to dampen unwanted immune responses upon subsequent allergen exposure.
  • Experiments demonstrated that microparticle treatment injections must be delivered locally near the site of allergen exposure (ear), whereas distal treatment (abdomen) failed to proliferate Tregs at the ear.
  • Interestingly, abdominal microparticle treatments followed by allergen exposure is capable of eliciting a systemic hyporesponsiveness that significantly reduces ear swelling when exposed to subsequent allergen challenges without any local prophylaxis.
  • This experimental data in mice suggests that prophylactic treatment during exposure and sensitization to a particular allergen could significantly suppresses immune dysfunction upon subsequent exposures anywhere on the body.
  • Considering that PEG-PLGA microparticle treatments can induce specific Tregs to suppress specific allergen mediated response, this modality offers a promising translatable novel treatment concept that could be used to decrease immune reactivity to known allergens inducing dermatitis.

 

For original article please visit: https://www.ncbi.nlm.nih.gov/pubmed/28694031 or http://www.sciencedirect.com/science/article/pii/S0168365917307046?via%3Dihub

Free Webinar – Complementary-Alternative Tx for eczema

Webinar – Complementary and Alternative Treatments for Eczema

If you’ve ever looked up “how to treat eczema” on the internet, no doubt you’ve seen every type of diet, herb or ointment under the sun. Dr. Peter Lio is here to clear up the confusion by presenting those complementary and alternative eczema treatments that are shown to be effective through rigorous, scientific research. Register for free today.

Wednesday, September 13, 2017
5:00 p.m. PDT/7:00 p.m. CDT/8 p.m. EDT

Presenter
Peter A. Lio, M.D.
Clinical Assistant of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine

Moderator
Karey Gauthier, M.S.
Associate Director of Communications, National Eczema Association

T.R.U.E. Test (patch test) receives pediatric indication

T.R.U.E Pediatric indication: T.R.U.E. Test (patch test) receives approval letter from Food and Drug Administration (FDA) for children 6 and older. After 12 years of investigations, evidence and data indicating that the patch testing is safe and efficacious in children suffering from recalcitrant dermatitis – the FDA has approved T.R.U.E Pediatric indication – the use of TRUE test to aid in the diagnosis of ACD in children.

This is the first commercially available patch test to receive approval for use in children 6 and older.  The T.R.U.E. test has 36 components, one is a negative control.

To read more about patch testing in children:

Article on Pediatric Allergic Contact Dermatitis.

“August 25, 2017

Dear Ms. Sullivan:
SUPPLEMENT APPROVAL PMR FULFILLED
August 25, 2017
We have approved your request dated October 26, 2016, to supplement your Biologics License Application submitted under section 351(a) of the Public Health Service Act (42 U.S.C. 262) for Thin-layer Rapid Use Epicutaneous Patch Test (T.R.U.E. TEST), to use as an aid in the diagnosis of allergic contact dermatitis in persons 6 years of age and older whose history suggests sensitivity to one or more of the 35 substances included on the T.R.U.E. TEST panels.”

FDA indication
Approval letter

MI contact allergy up!

31689 patients evaluated —  the prevalence of contact allergy to methylisothiazolinone went up to around 20% in several departments!
2017 Jun 19. doi: 10.1111/jdv.14423. [Epub ahead of print]

“European Surveillance System on Contact Allergies (ESSCA): results with the European baseline series, 2013/14.

Abstract

BACKGROUND:

Contact allergy is a common condition and can severely interfere with daily life or professional activities. Due to changes in exposures, a consequence of introduction of new substances, new products or formulations, and regulatory intervention, the spectrum of contact sensitisation changes.

OBJECTIVE:

To evaluate the current spectrum of contact allergy to allergens present in the European baseline series (EBS) across Europe.

METHODS:

Retrospective analysis of data collected by the European Surveillance System on Contact Allergies (ESSCA, www.essca-dc.org) in consecutively patch tested patients, 2013/14, in 46 departments in 12 European countries.

RESULTS:

Altogether, 31689 patients were included in the analysis. Compared to a similar analysis in 2004, the prevalence of contact allergy to methylisothiazolinone went up to around 20% in several departments. In comparison, contact allergy to the metals nickel, cobalt and chromium remained largely stable, at 18.1, 5.9 and 3.2%, respectively, similar to mostly unchanged prevalences with fragrance mix I, II and Myroxylon pereirae (Balsam of Peru) at 7.3, 3.8 and 5.3%, respectively. In the subgroup of departments diagnosing (mainly) patients with occupational contact dermatitis, the prevalence of work-related contact allergies such as to epoxy resin or rubber additives was increased, compared to general dermatology departments.

CONCLUSION:

Continuous surveillance of contact allergy based on network data offers the identification of time trends or persisting problems, and thus enables focussing in-depth research (subgroup analyses, exposure analysis) on areas where it is needed.”

This article is protected by copyright. All rights reserved.

https://www.ncbi.nlm.nih.gov/pubmed/28627111

New Nickel Quiz

Take this new Nickel Quiz and test your savvy.  A study of 125,478 people with a nickel sensitivity, showed that developing allergic dermatitis, increases the risk of multiple sensitizations.

The quizzes are an educational endeavor created by the DA scholars to help promote awareness of contact dermatitis.

Nickel Quiz Here

Loma Linda University researchers are investigating the impact of nickel allergy – please share the nickel allergy survey and increase the knowledge…

Nickel Allergy Survey

 

Thank you!